Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 3 February 1989:
Vol. 243. no. 4891, pp. 660 - 663
DOI: 10.1126/science.2536954
Prev | Table of Contents | Next

Articles

Science, Vol 243, Issue 4891, 660-663
Copyright © 1989 by American Association for the Advancement of Science

articles

Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes

S Seremetis, G Inghirami, D Ferrero, EW Newcomb, DM Knowles, GP Dotto, and R Dalla-Favera

Department of Pathology, New York University, NY 10016.

The biological effects of ras oncogene activation in B cells were studied by using amphotropic retroviral vectors to introduce H- or N-ras oncogenes into human B lymphoblasts immortalized by Epstein-Barr virus. Expression of both H- and N-ras oncogenes led to malignant transformation of these cells, as shown by clonogenicity in semisolid media and tumorigenicity in immunodeficient mice. In addition, terminal differentiation into plasma cells was detectable as specific changes in morphology, immunoglobulin secretion, and cell surface antigen expression. This combined effect, promoting growth and differentiation in human lymphoblasts, represents a novel biological action of ras oncogenes and has implications for the pathogenesis of terminally differentiated B-lymphoid malignancies such as multiple myeloma.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.
T. Rasmussen, M. Kuehl, M. Lodahl, H. E. Johnsen, and I. M. S. Dahl (2005)
Blood 105, 317-323
   Abstract »    Full Text »    PDF »
Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors.
F. Bovia, P. Salmon, T. Matthes, K. Kvell, T. H. Nguyen, C. Werner-Favre, M. Barnet, M. Nagy, F. Leuba, J.-F. Arrighi, et al. (2003)
Blood 101, 1727-1733
   Abstract »    Full Text »    PDF »
Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation.
N. Kalakonda, D. G. Rothwell, J. H. Scarffe, and J. D. Norton (2001)
Blood 98, 1555-1560
   Abstract »    Full Text »    PDF »
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process.
M. Hallek, P. Leif Bergsagel, and K. C. Anderson (1998)
Blood 91, 3-21
   Full Text »    PDF »
A Novel Chromosomal Translocation t(4; 14)(p16.3; q32) in Multiple Myeloma Involves the Fibroblast Growth-Factor Receptor 3 Gene.
R. Richelda, D. Ronchetti, L. Baldini, L. Cro, L. Viggiano, R. Marzella, M. Rocchi, T. Otsuki, L. Lombardi, A. T. Maiolo, et al. (1997)
Blood 90, 4062-4070
   Abstract »    Full Text »    PDF »
Growth factors and cancer.
S. Aaronson (1991)
Science 254, 1146-1153
   Abstract »    PDF »
Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells.
G Inghirami, F Grignani, L Sternas, L Lombardi, D. Knowles, and R Dalla-Favera (1990)
Science 250, 682-686
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)